Adverum Biotechnologies Inc (FRA:AVU0)
€ 5.45 -0.05 (-0.91%) Market Cap: 116.09 Mil Enterprise Value: 40.31 Mil PE Ratio: 0 PB Ratio: 0.85 GF Score: 31/100

Adverum Biotechnologies Inc at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 10:30PM GMT
Release Date Price: €101 (+8.02%)
Unidentified Analyst

Good afternoon, everyone. My name is [Ray Wang], and I am a member of the JPMorgan health care investment banking team. Thank you all for coming here today. And now it is my pleasure to introduce Leone Patterson, Chief Executive Officer of Adverum Biotechnologies.

Leone D. Patterson
Adverum Biotechnologies, Inc. - President, CEO & Director

All right. Thanks, everyone, for coming. Yes, we are a gene therapy company in the clinic. And today, my conversation is going to be with you around really the progress that we've made in the last 12 months, which has been significant. I mean I've been with the company for over 3 years, but I can tell you the progress that's been made in the last 12 months is really phenomenal. And what I'm going to cover today is that progress along with the clinical data that we just presented this past weekend at a scientific conference. And what are we talking about here is this lead program, ADVM-022, which we're now in the clinic. And this is transformative technology that we believe has the potential to change the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot